Clinical Trials in Pennsylvania

Showing 7341-7360 of 14,950 trials

QuikClot Control+ Hemostatic Dressing Use in Mild to Moderate Bleeding

NCT04415606

QuikClot Control+ Hemostatic Dressing (QuikClot+) is indicated for temporary control of internal organ space bleeding for patients displaying Class III or Class IV Bleeding. It may also be used for control of severely bleeding wounds such as surgical wounds and traumatic injuries. QuikClot Control+ is also indicated for temporary control of mild to moderate bleeding in cardiac surgical procedures. QuikClot Control+ is also indicated for use to control bleeding from bone surface following sternotomy.

Hemostasis

Z-Medica266 participantsStarted Jun 2020

Aurora, Colorado, United States • Atlanta, Georgia, United States • Pocatello, Idaho, United States +4 more locations

COMPLETEDPhase 282 miles

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

NCT00628095

CE-224,535 is known to block a chemical that acts as a gateway to some of your immune cells. Blocking this gateway prevents the cells from pushing out 2 chemicals called IL-1 and IL-18 that are known to cause some of the inflammation seen in rheumatoid arthritis. It is hoped that taking this drug will reduce the symptoms of rheumatoid arthritis

Arthritis, Rheumatoid

Pfizer100 participantsStarted Apr 2008

Mesa, Arizona, United States • DeBary, Florida, United States • Lake Mary, Florida, United States +24 more locations

QuikClot Control+ Hemostatic Dressing Use in Mild to Moderate Bleeding

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

Find Trials by Condition in Pennsylvania

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

A Study of Oral Contraception Under Simulated OTC Conditions

An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps

Reducing Involuntary Movements in Participants With Tardive Dyskinesia

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

The National Standard for Normal Fetal Growth

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)

Repeat Antenatal Steroids Trial

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure

Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children

PERL Continuous Glucose Monitoring (CGM) Study

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age

Parents Advancing Toddler Health